

# Food & Function

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

*Accepted Manuscripts* are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1 **Title: Influence of milk fermented by *Lactobacillus rhamnosus* NCDC 17 alone and in**  
2 **combination with herbal ingredients on diet induced adiposity and related gene**  
3 **expression in C57BL/6J mice**

4

5

6 **Ramesh Pothuraju\*, Raj Kumar Sharma, Jayasimha Chagalamarri, Praveen Kumar**  
7 **Kavadi and Surender Jangra**

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

Division of Animal Biochemistry,  
National Dairy Research Institute, Karnal-132001,  
Haryana (India)  
\*Corresponding E-mail address: rameshbabu933@gmail.com

## 1 **Abstract**

2 Obesity has become a major health problem in developed countries and is rapidly catching up  
3 in the developing world due to change in the life style. Dietary incorporation of functional  
4 foods, including probiotic fermented milk and herbal ingredients is being tried to ameliorate  
5 the metabolic disorders. In the present study, the effects of dietary supplementation of a  
6 probiotic (*Lactobacillus rhamnosus* NCDC 17) fermented milk alone or either of herbal  
7 preparations (*Aloe vera*/*Gymnema sylvestre* powders, 1% w/w) on progression of obesity has  
8 been studied in high fat diet fed C57BL/6J mice for 12 weeks. At the end of experimental  
9 period, oral administration of *L. rhamnosus* and herbs showed a significant decrease in the  
10 body weight, epididymal fat mass, fasting blood glucose and serum insulin levels.

11 Supplementation of probiotic *L. rhamnosus* NCDC 17 alone and in combination with herbs  
12 showed a significant decrease in the adipocyte cell size and increase in the number. Finally,  
13 obesity related adipokines levels were maintained to normal by the treatment groups. Thus,  
14 dietary intervention of milk fermented with probiotic *L. rhamnosus* alone or in combination  
15 with any of the herbal preparations seems to exhibit anti-obesity and anti-inflammatory  
16 properties.

17

18

19

20

21

22

23

24

25

## 1 Introduction

2 Obesity is associated with multi-factorial disorders, in which excessive fat is accumulated in  
3 the adipose tissue results in increased energy consumption and decreased energy  
4 expenditure.<sup>1</sup> The accumulation of ample fat inside the body leads to many pathological  
5 diseases such as insulin resistance, type 2 diabetes mellitus (T2DM), ischaemic heart disease,  
6 retinopathy, neuropathy and cancer, which can lead to failure of several organs and termed as  
7 metabolic syndrome or syndrome X.<sup>2</sup> Current pharmacological treatments are not successful  
8 in cutting down the weight gain and its related disorders.<sup>3</sup> Therefore, alternative therapies are  
9 emerging the aforesaid diseases.

10 The gut microbiota are supposed to play an important role towards obesity, however,  
11 this is still controversial. More than  $10^{12}$  microorganisms are inhabited in the gastrointestinal  
12 (GI) tract.<sup>4</sup> The major phyla includes *firmicutes* and *bacteroides*<sup>5</sup> and alteration of above  
13 phyla occurs in the GI tract of obese and lean subjects. Probiotics are defined as live  
14 microorganisms when administered in an adequate amounts confer a health benefit on the  
15 host.<sup>6</sup> Now-a-days, researchers have keen interest in using probiotic organisms like  
16 lactobacilli and bifidobacteria species for their anti-obesity effects.<sup>7</sup> Several probiotics  
17 showed different effects on gut microbiota and obesity.<sup>8</sup> Intra-gastric gavage administration  
18 of *Lactobacillus rhamnosus* PL 60 fed to high fat diet mice showed a decrease in the body  
19 weight gain and epididymal fat mass.<sup>9</sup> In another study, *Lactobacillus rhamnosus* GG showed  
20 a significant reduction of epididymal fat mass and obesity related biomarkers in the liver  
21 (*viz.*, acetyl-CoA carboxylase, fatty acid synthase and stearyl CoA desaturase-I) of obese  
22 mice.<sup>10</sup>

23 Now-a-days, plant extracts are having great attention as a therapeutic weapons for the  
24 treatment of obesity and its associated diseases. Both *Aloe vera* (AV) and *Gymnema sylvestre*  
25 (GS) extracts have been widely used for their anti-obesity and anti-diabetic effects since

1 ancient periods.<sup>11,12</sup> Shin and co-workers<sup>13</sup> reported that dietary aloe formulas showed  
2 reduction in the anti-inflammatory markers in white adipose tissue of obese mice.  
3 Administration of the dried AV gel powder showed decrease of body weight, visceral fat  
4 weight, body fat and serum lipids in obese rats.<sup>14</sup> In another report, *Aloe vera* phytosterols  
5 administration displayed decreased in the random and fasting blood glucose levels and  
6 reduced visceral fat weights in Zucker Diabetic Fatty (ZDF) rats.<sup>15,16</sup> Similarly, GS  
7 supplementation also showed decrease body mass index, visceral fat pad weight, serum lipids  
8 in high fat diet (HFD) fed rodents.<sup>17-19</sup> The active components (gymnemic acid IV fraction  
9 and dihydroxy gymnemic triacetate) isolated from *Gymnema sylvestre* displayed  
10 hypoglycemic and hypolipidemic effects in diabetic rats.<sup>20,21</sup>

11 The bioactive components (acemannan, aloin & gymnemic acids) present in the AV  
12 and GS may be responsible for the growth and metabolic activity of lactobacilli strains during  
13 fermentation. Further, it can excite to examine the effects of administration of herbal  
14 ingredients together with the probiotics. There is a paucity of information on anti-obesity of  
15 indigenous strains of lactobacilli. Moreover, even contradictory findings have also been  
16 available in the literature regarding probiotic lactobacilli species. In our previous study,  
17 *Lactobacillus rhamnosus* NCDC 17 (LR17) strain was selected from four different  
18 lactobacilli strains and exhibited good probiotic attributes *viz.*, such as acid tolerance, bile  
19 tolerance and surface hydrophobicity under *in vitro* conditions.<sup>22</sup> In addition, LR17 exhibited  
20 angiotensin-converting enzyme inhibitory and extent of proteolysis activities which are  
21 linked with anti-hypertensive effect.<sup>23</sup> Accordingly, the present investigation was carried out  
22 to study anti-obesity effects of milk fermented by LR17 alone or in combination with herbal  
23 extracts (AV/GS) in HFD fed C57BL/6J mice.

24

25

## 1 **Experimental**

2 This section describes the experimental details of the study conducted using obesity prone  
3 C57BL/6J mice. The effects of probiotic (LR17) and two types of herbal preparations *viz.*,  
4 AV and GS were investigated in mice fed HFD for 12 weeks duration.

### 5 **Probiotic culture and preparation of fermented milk**

6 Probiotic culture (LR17) was obtained from the National Collection of Dairy Cultures  
7 (NCDC, Dairy Microbiology Division) of the institute. Skim milk (SM) was obtained from  
8 experimental dairy of the institute, heated to 90 °C for 30 min and cooled to room  
9 temperature without exposing to air. The activated culture of LR17 was inoculated at 1%  
10 (v/v) level and incubated at 37 °C for 18 h. After that, the prepared fermented milk was  
11 stored at refrigeration temperature (4 °C) and fed to the respective groups. The viable counts  
12 were determined on MRS agar. An appropriate quantity of fermented milk was diluted with  
13 0.85 % saline and mixed uniformly with a vortex mixer. Serial dilutions were prepared and  
14 proper dilutions were plated on MRS agar by pour plating method and colony counting done  
15 in a routine manner. Milk fermented with LR17 contained viable counts was in the range of  
16 8.0 to 8.5 log cfu mL<sup>-1</sup>.

### 17 **Herbal ingredients**

18 *Aloe vera* gel powder (200x) containing 8.8% aloin was procured from M/s Indichem,  
19 Mumbai while *Gymnema sylvestre* powder containing 75% gymnemic acids was a product of  
20 M/s Ambe Phytoextracts Pvt. Ltd, New Delhi. The herbal powder (AV/GS) was added to  
21 HFD at 1% w/w level.

### 22 **Animals and treatment**

23 Thirty male C57BL/6J mice (25-28 g) were obtained from National Institute of Nutrition,  
24 Hyderabad (India). The animals were acclimatized on normal chow for 1 week under 12 h  
25 light/dark conditions at 22 ± 1 °C and 50 ± 10 % relative humidity and were fed *ad libitum* on

1 respective diets. The experiment was carried out in accordance with the guidelines of the  
2 institutional animal ethics committee.

3 After an acclimatization period, the mice were randomly divided into six groups (n=6/group,  
4 3 mice/cage) and fed with control + SM, HFD + SM (60 kcal% fat), HFD + LR17, HFD +  
5 AV + LR17 and HFD + GS + LR17 for 12 weeks. These were designated as CTRL, HFD,  
6 HFD-LR, HFD-AVLR and HFD-GSLR, respectively. The HFD or HFD containing the  
7 herbal ingredient was presented to animals during the dark phase (5:00 pm-9:30 am), while  
8 skim or fermented milk was fed in light phase (9:30 am-5:00 pm). The solid diet was  
9 removed from the cages during light phase to ensure that the animals could consume their  
10 respective liquid diets. The compositions of diets are given in Table 1. Body weights were  
11 taken at weekly intervals. At the final stage of the experimental period, mice were sacrificed  
12 by cervical dislocation under anaesthesia using diethyl ether and blood was collected by  
13 cardiac puncture to determine serum insulin and lipid profile. Liver, spleen, kidney and  
14 epididymal fat (E.fat) were collected and weighted. A portion of epididymal adipose tissue  
15 was stored in buffered formalin (10%) for determination of adipocyte size and number. The  
16 rest of the portion of E.fat was stored in RNAlater at -20 °C for gene expression study.

#### 17 **Analysis of fasting blood glucose level**

18 The fasting blood glucose levels were determined at 0, 6 and 12 weeks by using a glucometer  
19 (Accu-Chek® active, Roche Diagnostics, Germany) and comparisons were made between the  
20 different groups.

#### 21 **Oral glucose tolerance test (OGTT)**

22 Before the end of experiment, mice from different treatment groups were fasted for 12 h and  
23 then administered glucose solution by intragastric gavage (1.0 g kg<sup>-1</sup> b.wt, 20% glucose  
24 solution). Blood samples were drawn by puncturing the tail vein with needle gun and glucose

1 levels were measured at 0, 30, 60 and 120 min after glucose administration, using a  
2 glucometer.

### 3 **Determination of serum and liver lipids**

4 Serum total cholesterol (TC), triglycerides (TG) and HDL-cholesterol levels were estimated  
5 enzymatically using the kit according to manufacturer's instructions (Span Diagnostics Ltd,  
6 Surat, India). A Friedewald's equation was used for the calculation of VLDL and LDL-  
7 cholesterol levels. To determine liver lipids, tissue (100 mg) was homogenized in one mL of  
8 isopropanol and shaken for 45 min. The samples were centrifuged at 3000 g for 10 min to  
9 collect the supernatant and TG & TC levels were analysed using commercial enzymatic  
10 kits.<sup>16</sup>

### 11 **Measurement of insulin and HOMA index**

12 Serum insulin levels were measured by sandwich ELISA (Crystal chem. Inc, USA). Insulin  
13 resistance was assessed by homeostasis model assessment (HOMA-IR). It was calculated by  
14 multiplying fasting serum insulin ( $\mu\text{U L}^{-1}$ ) with fasting blood glucose ( $\text{mM L}^{-1}$ ) divided by  
15 22.5.<sup>24</sup>

### 16 **Histological analysis**

17 After sacrificing mice, epididymal fat tissue was taken from three animals in each group (3  
18 replicates/sample). These were fixed at 10 % (v/v) neutral-buffered formalin and embedded  
19 in paraffin, sectioned (4  $\mu\text{m}$  thickness) and mounted on glass slides. Hematoxylin-eosin  
20 stained slides were examined (3 fields/spot) under magnification x 200 (Nikon, Eclipse Ti-S,  
21 Japan). Images were taken and cell size & number were determined using Image J software  
22 (National Institutes of Health, Bethesda, MD, USA).

23

24

25



## 1 Analysis of mRNA expression of genes in epididymal fat

2 Total RNA was isolated from epididymal fat by using TRIzol (Sigma-Aldrich, USA). The  
3 purity was determined by spectrophotometrically on the basis of  $A_{260}/A_{280}$  ratio, while  
4 integrity was checked by agarose gel electrophoresis. The cDNA template was synthesised by  
5 reverse transcription of 500 ng of total RNA using first strand cDNA synthesis kit (Thermo  
6 scientific, USA). SYBR Green was used for real-time PCR detection. The primers  
7 (adiponectin, leptin, resistin, PPAR $\gamma$ , UCP2, TNF- $\alpha$  and IL-6) used for qRT-PCR are listed in  
8 Table 2.  $\beta$ -actin was used as a reference gene. All samples were analysed in duplicate in a 96-  
9 well reaction plate and the data was analysed according to the  $2^{-\Delta\Delta CT}$  method.

## 10 Statistical analysis

11 All data were expressed as mean  $\pm$  SEM. Statistical analysis was done with one or two way  
12 ANOVA using Tukey's tests (GraphPad Software, version 5.01) for body and organ weights,  
13 fasting blood glucose, serum & liver lipids, insulin, OGTT, HOMA-IR and gene expression.

## 14 Results

### 15 Body weight and organ weights

16 As shown in Table 3, high fat diet fed mice showed an increase in the body weight gain over  
17 12 weeks experimental period ( $27.29 \pm 0.71$ g, mean  $\pm$  SEM). Administration of fermented  
18 milk containing LR ( $25.18 \pm 0.55$ g,  $p < 0.05$ ) alone and in combination with herbs showed  
19 lowering of the body weight. However, a significant difference was observed in the presence  
20 of HFD-GSLR ( $25.20 \pm 0.41$ g,  $p < 0.05$ ) fed group.

21 High caloric intake results accumulation of energy in the form of body fat, i.e.  
22 epididymal fat, was significantly higher in HFD fed ( $1.10 \pm 0.09$  g) mice. The weight of  
23 epididymal fat pad was significantly ( $p < 0.05$ ) decreased in all treatments and the values were  
24 found to be  $0.55 \pm 0.11$ ,  $0.68 \pm 0.07$  and  $0.64 \pm 0.09$  g for HFD-LR, HFD-AVLR and HFD-

1 GSLR fed groups, respectively. No significant difference was observed in the weight of liver  
2 and kidney among the different dietary interventions.

### 3 **Fasting blood glucose level**

4 In Fig 2, fasting blood glucose levels were determined at 0, 6 and 12 weeks, respectively.  
5 High fat diet fed obese mice showed a significant increase in the glucose levels at 12 weeks  
6 ( $152.20 \pm 6.96 \text{ mg dL}^{-1}$ ,  $p < 0.05$ ). Oral administration of probiotic LR ( $100.20 \pm 7.58 \text{ mg dL}^{-1}$ ,  
7  $p < 0.05$ ) and a combination of herbs showed decreases in the circulatory glucose levels  
8 whereas, GS-LR fed group ( $118.20 \pm 7.61 \text{ mg dL}^{-1}$ ) alone made a significant contribution.

### 9 **Glucose tolerance test**

10 In OGTT experiment, HFD fed mice exhibited a significant increase in the blood glucose  
11 levels upon glucose loading compared to control group. As shown in (Fig. 1),  
12 supplementation with LR alone or in combination with GSLR in HFD fed mice showed a  
13 remarkable lowering of glucose levels during 30 and 60 min while, similar results were also  
14 observed in the case of area under the curve (AUC).

### 15 **Serum and liver lipids**

16 The serum and liver lipids were analysed for all treatment groups (Table 3). Serum TG levels  
17 ( $131.20 \pm 6.87 \text{ mg dL}^{-1}$ ) were found to be significantly higher in HFD group.  
18 Supplementation of probiotic LR ( $90.95 \pm 7.73 \text{ mg dL}^{-1}$ ) alone and in combination with  
19 herbal extracts AV/GS ( $87.64 \pm 6.85/84.45 \pm 8.69 \text{ mg dL}^{-1}$ ) displays a significantly decreased  
20 in the TG levels. No effect was observed with the remaining serum lipids. In other hand, a  
21 significant decreased in hepatic TG levels were observed with LR alone ( $11.93 \pm 1.01$ ) either  
22 of AV/GS ( $9.90 \pm 1.42/13.46 \pm 0.60$ ) compared to HFD ( $18.45 \pm 0.52 \text{ mg g}^{-1} \text{ tissue}$ ) fed  
23 group. However, no significant difference was observed with liver TC levels in all dietary  
24 interventions.

25

### 1 **Serum insulin and HOMA-IR index**

2 In Table 3, serum insulin and IR index values were presented. Serum insulin concentrations  
3 were significantly higher in HFD fed group and observed to be  $172.90 \pm 24.28 \text{ pmol L}^{-1}$ .

4 These insulin levels were significantly reverted back to normal with probiotic LR ( $76.19 \pm$   
5  $9.54 \text{ pmol L}^{-1}$ ) alone and in combination with herbs AV/GS with the values of  $98.14 \pm 8.07$   
6 and  $86.51 \pm 5.89 \text{ pmol L}^{-1}$ , respectively. Similar results were found with the calculated  
7 HOMA-IR index values.

### 8 **Adipocyte size and number**

9 Histological analysis of epididymal fat showed that the cell size was significantly increased  
10 and the number was decreased significantly in HFD fed group. Oral administration of LR  
11 alone or in combination with herbal ingredients (AVLR/GSLR) showed a significant positive  
12 effect in obese mice (Fig. 3).

### 13 **Quantitative real time PCR**

14 Further, we measured the gene expression analysis in epididymal fat tissue (Fig. 4).  
15 Adipokines which are involved in the energy metabolism, i.e. adiponectin (AdipoQ) and  
16 UCP2 expression levels were down regulated in HFD group. Milk fermented by probiotic LR  
17 alone and in combination with herbs showed a significant up regulation of both AdipoQ and  
18 UCP2 mRNA expression. However, leptin and resistin gene expression was up regulated in  
19 HFD fed group, these expression levels were significantly reverted back to normal upon  
20 probiotic LR alone and in combination with GS supplementation. In contrast, no significant  
21 difference was observed with PPAR $\gamma$  expression in all different dietary interventions. Pro-  
22 inflammatory cytokines (TNF- $\alpha$  and IL-6) were significantly increased in HFD fed group.  
23 Administration of milk fermented by LR alone and in combination with both AV/GS  
24 significantly decreased inflammatory marker genes.

25

## 1 Discussion

2 The feeding of milk fermented *Lactobacillus rhamnosus* NCDC 17 showed a significant  
3 reduction in body weight gain in HFD fed group. Few reports are available on the anti-  
4 obesity effect of LR probiotic culture. Our results were consistently similar to Lee and co-  
5 workers<sup>9</sup> observed that *L. rhamnosus* PL60 administration to HFD fed mice showed a  
6 significant reduction in the body weight and no effect on feed intake. In contrary, Ji *et al.*<sup>10</sup>  
7 studied that oral administration of *Lactobacillus rhamnosus* GG (LGG) did not show any  
8 significant effect in the reduction of body weight and feed intake compared to normal chow  
9 fed mice. In a recent report by Kumar *et al.*<sup>25</sup> also observed that no significant effect on body  
10 weight gain and feed intake in hypercholesterolemic rats by LGG strain. Oral administration  
11 of milk fermented by LR culture in combination with AV had no effect on reduction in the  
12 body weight. Similar results were obtained by Kumar and co-workers<sup>25</sup> upon administration  
13 of *Aloe vera* gel extract and in combination with LGG in hypercholesterolemic rats.  
14 Moreover, GSLR showed reduction in the body weight gain. To the best of our knowledge,  
15 no reports are available with probiotic in combination with GS extract. In this study, reducing  
16 body weight gain and epididymal fat mass in the HFD mice was due to increasing energy  
17 expenditure. The increase in the energy expenditure is associated with less fat accumulation  
18 via mRNA expression of uncoupling protein (UCP2). On the other hand, conjugated linoleic  
19 acid (trans-10, cis-12-CLA) produced by the lactobacilli might be responsible to decrease  
20 body weight gain with unknown mechanism.<sup>9,26</sup> The contradictory results were observed due  
21 to lactobacilli strain specific and route of administration and treatment length.

22 Insulin plays an important role in the regulation of glucose homeostasis and lipid  
23 metabolism. Body weight gain and fat deposition were responsible for insulin resistance  
24 which results failure of target organs (adipose tissue and muscle) for the action of insulin and  
25 associated with metabolic abnormalities such as glucose intolerance, hyperlipidaemia, hepatic

1 steatosis, and hypertension as occurs.<sup>27-30</sup> The high fat diet fed obese mice showed a  
2 significant increase in glucose and insulin levels after 12 weeks experimental period. These  
3 were decreased by lactobacilli (LAB) culture alone and in combination with *Aloe vera* and  
4 *Gymnema sylvestre* extracts. The results on blood glucose levels in the present study suggest  
5 that the effects of probiotic fermented milk may be due to the improvement of insulin  
6 sensitivity. This is also supported by the insulin levels measured by ELISA in probiotic fed  
7 groups. Hypoglycemic effect of *Aloe vera* might be associated with pancreatic insulin  
8 synthesis and its secretion responsible for the lowering of circulatory glucose levels<sup>31</sup>  
9 whereas, gymnemic acids present in the *Gymnema sylvestre* binds to the glucose receptors to  
10 prevent the intestinal glucose absorption.<sup>12</sup>

11 A high-fat intake results in increased levels of free fatty acids in the circulation.<sup>31,32</sup>  
12 Administration of NCDC lactobacilli culture alone and in combination with herbs displayed a  
13 significant reduction in the serum triglycerides levels in DIO mice. Similar to our results, Lee  
14 *et al.*<sup>9</sup> observed that *L. rhamnosus* PL60 showed no effect on serum TC and LDL-C levels in  
15 diet induced obese mice. Recently, Kumar *et al.*<sup>25</sup> stated that *Lactobacillus rhamnosus* GG  
16 administration to hypercholesterolemic rats showed a decrease in the serum lipids (TC, TG,  
17 VLDL-C, LDL-C) levels. Next, we measured the hepatocyte lipid (TG and TC) levels after  
18 12 weeks. The liver is responsible for the utilization of fatty acids from the HFD diet to  
19 synthesize cholesterol and triglycerides. High fat intake of mice results alteration in the lipid  
20 metabolism, resulting in accumulation of fat in the hepatocyte.<sup>33</sup> Administration of lactic acid  
21 bacteria (LAB) culture and in combination with both herbs showed a significant reduction in  
22 the lowering of liver TG and no effect on TC levels. However, phytosterols present in the  
23 herbs are don't extensively absorbed from the intestine, but it can bind to the lipids and  
24 prevent its absorption to show a hypolipidaemic effect.<sup>34</sup> Further, we determined the adipose  
25 tissue cell size and number. Administration of LAB culture alone and in combination with

1 both herbs showed a significant decrease in the cell size, whereas a significant increase in the  
2 number in HFD fed group. Our results were similar with other several LAB cultures showed  
3 reduction in the adipose tissue size in high fat diet mice.<sup>4,35</sup> To our contradictory results Lee  
4 *et al.*<sup>9</sup> reported that *L. rhamnosus* PL60 from human origin supplementation, the size of  
5 epididymal adipocytes was not reduced in DIO mice. The results suggest an accumulation of  
6 fat due to increase intake of energy by mice receiving high fat diet. Seemingly, the  
7 hypertrophic adipocytes produce abnormal adipokines and cytokines, including the  
8 inflammatory markers.

9 Furthermore, we analyzed mRNA expression of adipokines such as adiponectin  
10 (AdipoQ), leptin, resistin, PPAR $\gamma$ , UCP2 and pro-inflammatory genes (TNF- $\alpha$  and IL-6) in  
11 epididymal fat tissue by qRT-PCR method against  $\beta$ -actin used as a reference gene. The  
12 adiponectin secreted from the adipocytes played an important role in regulating energy  
13 homeostasis. It is responsible for the inactivation of AcetylCoA carboxylase via AMP  
14 activated protein kinase (AMPK) which ultimate activation of  $\beta$ -oxidation of fatty acids to  
15 decrease energy conservation. Our results demonstrated that, high fat diet fed mice exhibited  
16 a significant decrease and increase in the adiponectin and leptin mRNA expression. The  
17 adipoQ and leptin levels were significantly increased and decreased in all treatment groups  
18 (except AVLr) in obese mice. In other hand, no significant effect was observed in case of  
19 PPAR $\gamma$  expression. Kondo *et al.*<sup>36</sup> demonstrated that *bifidobacterium breve* strain B-3  
20 supplementation to HFD fed mice showed up regulation of adiponectin levels, whereas no  
21 effect on leptin and PPAR $\gamma$  expression. In addition, obese mice showed, mRNA expression of  
22 resistin was down regulated by different treatment groups. Major active principle compounds  
23 (anthraquinones, polyphenols and acemannan etc) present in the *Aloe vera* are becoming a  
24 major dietary energy source for the bacterial growth and metabolised in the large intestine.  
25 These compounds can't be degraded in the human gastrointestinal (GI) tract and converted

1 into short chain fatty acids (SCFAs) such as acetate, butyrate and propionate by the gut  
2 microbiota under anaerobic conditions. The SCFAs are bind to the G protein-coupled  
3 receptors/free fatty acid receptors (expressed in the intestine) to activate AMPK pathway for  
4 the  $\beta$ -oxidation of fatty acids to decrease adiposity.<sup>37</sup> SCFAs are stimulates anorexigenic gut  
5 hormones such as Glucagon like peptide-1 (GLP-1) and Peptide YY (PYY) which acts as a  
6 satiety effect by reducing energy utilization from the diet.

7 An increase in the energy expenditure results in a significant reduction of fat  
8 accumulation in the adipose tissue.<sup>38</sup> Genes play an important role involved in the increase of  
9 thermogenesis in adipose tissue. In our study, UCP2 mRNA expression levels were  
10 significantly increased after feeding a potential probiotic alone and in combination with  
11 herbs. Obesity and insulin resistance are associated with the excess accumulation of fat in the  
12 adipose tissue, leads to less vascularisation results hypoxia (less oxygen) and further  
13 infiltration of macrophages and inflammatory cytokines.<sup>28,30</sup> In the present study, both pro-  
14 inflammatory cytokines (TNF-  $\alpha$  and IL-6) were significantly down regulated by all dietary  
15 interventions. Probiotics are playing an important possible mechanism involved in down  
16 regulation of pro-inflammatory gene expression in the adipose tissue by improving the  
17 intestinal tight junction proteins (ZO1 and occludin) to prevent the lipopolysaccharide (LPS  
18 which is secreted from the harmful bacteria) binding to cytokine receptors present in the  
19 adipose tissue and liver. An increase in the circulator LPS levels results in metabolic  
20 endotoxemia, which further leads to inflammation and metabolic disorders.<sup>39,40</sup> The  
21 polysaccharide (acemannan) of *Aloe vera* is responsible for the activation of macrophages to  
22 secrete cytokines viz. TNF- $\alpha$ , IL-1, IL-6 and interferon- $\gamma$  or INF- $\gamma$ . The active components  
23 (anthraquinones, polyphenols and acemannan etc) present in the *Aloe vera* showed an anti-  
24 inflammatory activity by inhibiting the cyclooxygenase in the arachidonic acid pathway.<sup>41</sup>

25

## 1 **Conclusions**

2 Due to potential health benefits of probiotic lactobacilli species, they are widely used as food  
3 ingredients in the form of fermented milk products. The present results indicate that the milk  
4 fermented by probiotic LR alone and in combination of AVL/GSLR reduced body weight  
5 gain and epididymal fat mass. This is the first study where probiotic (LR) in combination  
6 with herbal ingredients were used. Further, lactobacilli and combination with both herbs  
7 showed decrease in epididymal fat cell size, fasting blood glucose, serum insulin and lipid  
8 levels. Relative mRNA expression analysis of obesity related genes in epididymal tissue  
9 suggested that a positive effect by all treatment groups. Though, this is an interesting active  
10 area of research to delineate the mechanistic aspects clearly as to how the probiotic live cells  
11 or their metabolic products change the gut environment. Fractionation of preparations from  
12 herbs like *A. vera* and *G. sylvestre* to study the effects of individual components may also be  
13 an important field of research to investigate their effectiveness in amelioration of diet induced  
14 obesity and insulin resistance.

## 15 **Acknowledgment**

16 We would like to thank the Director, ICAR-National Dairy Research Institute,  
17 Haryana (India), for providing the necessary facilities. The authors also thank Dr. Satish  
18 Devarapu for assisting in analysis of the adipocyte size and number by Image J analysis  
19 software (USA).

20

21

22

23

24



## 1 References

- 2 1 K. F. Wellen and G. S. Hotamisligi, *J. Clin. Invest.*, 2005, 115, 1111–1119.
- 3 2 G. M. Reaven, *Circulation.*, 2002, 106, 286–288.
- 4 3 A. M. Glenny, S. O'Meara, A. Melville A, T. A. Sheldon and C. Wilson, *Int. J. Obes. Relat. Metab. Disord.*, 1997, 21, 715–737.
- 5
- 6 4 D. Y. Park, Y. T. Ahn, S. H. Park, C. S. Huh, S. R. Yoo, R. Yu, M. K. Sung, R. A. McGregor and M. S. Choi, *PLoS One*, 2013, 8, e59470.
- 7
- 8 5 M. Arumugam, J. Raes, E. Pelletier, D. Le Paslier, T. Yamada, D. R. Mende, G. R. Fernandes, J. Tap, T. Bruls, J. M. Batto, M. Bertalan, N. Borrueal, F. Casellas, L. Fernandez, L. Gautier, T. Hansen, M. Hattori, T. Hayashi, M. Kleerebezem,
- 9
- 10 K. Kurokawa, M. Leclerc, F. Levenez, C. Manichanh, H. B. Nielsen, T. Nielsen, N. Pons, J. Poulain, J. Qin, T. Sicheritz-Ponten, S. Tims, D. Torrents, E. Ugarte, E. G. Zoetendal, J. Wang, F. Guarner, O. Pedersen, W. M. de Vos, S. Brunak, J. Doré, H. I. T. Meta, M. Consortium, Antolín, F. Artiguenave, H. M. Blottiere, M. Almeida,
- 11
- 12 C. Brechot, C. Cara, C. Chervaux, A. Cultrone, C. Delorme, G. Denariáz, R. Dervyn, K. U. Foerstner, C. Friss, M. van de Guchte, E. Guedon, F. Haimet, W. Huber, J. van Hylckama-Vlieg, A. Jamet, C. Juste, G. Kaci, K. Knol, O. Lakhdari, S. Layec, K. Le Roux, E. Maguin, A. Mérieux, R. Melo, Minardi, C. M'rini, J. Muller, R. Oozeer, J. Parkhill, P. Renault, M. Rescigno, N. Sanchez, S. Sunagawa, A. Torrejon, K. Turner,
- 13
- 14 G. Vandemeulebrouck, E. Varela, Y. Winogradsky, G. Zeller, J. Weissenbach, S. D. Ehrlich and P. Bork, *Nature.*, 2011, 473, 174–180.
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22 6 FAO and WHO. Health and Nutritional Properties of Probiotics in Food including Powder Milk with Live Lactic Acid Bacteria. Report of joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food
- 23
- 24

- 1 including powder milk with live lactic acid bacteria. Cordoba, Argentina, 2001, October  
2 1–4, pp. 19–20.
- 3 7 S. A. Rather, R. Pothuraju, R. K. Sharma, S. De, N. A. Mir and S. Jangra, *Int. J. Dairy*  
4 *Technol.*, 2014, doi,10.1111/1471-0307.12154.
- 5 8 N. P. McNulty, T. Yatsunenko, A. Hsiao, J. J. Faith, B. D. Muegge, A. L. Goodman,  
6 B. Henrissat, R. Oozeer, S. Cools-Portier, G. Gobert, C. Chervaux, D. Knights, C.  
7 A. Lozupone, R. Knight, A. E. Duncan, J. R. Bain, M. J. Muehlbauer, C. B. Newgard,  
8 A. C. Heath and J. I. Gordon, *Sci. Transl. Med.*, 2011, 3, 106.
- 9 9 H. Y. Lee, J. H. Park, S. H. Seok, M. W. Baek, D. J. Kim, K. E. Lee, K. S. Paek, Y. Lee  
10 and J. H. Park, *Biochim. Biophys. Acta.*, 2006, 1761, 736–744.
- 11 10 Y. S. Ji, H. N. Kim, H. J. Park, J. E. Lee, S. Y. Yeo, J. S. Yang, S. Y. Park, H. S. Yoon,  
12 G. S. Cho, C. M. Franz, A. Bomba, H. K. Shin and W. H. Holzapfel, *Benef. Microbes.*,  
13 2012, 3, 13–22.
- 14 11 R. Pothuraju, R. K. Sharma and N. R. Panjagari, *Curr. Nutr. Food Sci.*, 2014a, 10, 1-10.
- 15 12 R. Pothuraju, R. K. Sharma, J. Chagalamarri, S. Jangra and P. Kumar Kavadi, *J. Sci.*  
16 *Food Agric.*, 2014b, 94, 834–840.
- 17 13 E. Shin, K. S. Shim, H. Kong, S. Lee, S. Shin, J. Kwon, T. H. Jo, Y. I. K. Lee and  
18 K. Kim, *Immune Netw.*, 2011, 11, 59–67.
- 19 14 E. Misawa, M. Tanaka, K. Nabshima, M. Yamada, T. Toida and K. Iwatsuki, *J. Nutr.*  
20 *Sci. Vitaminol.*, 2012a, 58, 195–201.
- 21 15 E. Misawa, M. Tanaka, K. Nomaguchi, M. Yamada, T. Todia and K. Iwatsuki, *Obes.*  
22 *Res. Clin. Pract.*, 2008, 2, 239–245.
- 23 16 E. Misawa, M. Tanaka, K. Nabeshima, M. Yamada, T. Todia and K. Iwatsuki, *J.*  
24 *Agric. Food Chem.*, 2012b, 60, 2799–2806.

- 1 17 N. Shigematsu, R. Asano, Y. Shimosaka and M. Okazaki, *Biol. Pharm. Bull.*, 2011, 24,  
2 713–717.
- 3 18 R. M. Reddy, T. Vijaya, P. B. Latha and D. S. Rao, *J. Pharm. Res.* 2011, 4, 1237–1239.
- 4 19 V. Kumar, U. Bhandari, C. D. Tripathi and G. Khanna, *Indian J. Pharmacol.*, 2012, 44,  
5 607–613.
- 6 20 Y. Sugihara, H. Nojima, H. Matsuda, T. Murakami, M. Yoshikawa and I. Kimura, *J.*  
7 *Asian Nat. Prod. Res.*, 2000, 2, 321–327.
- 8 21 P. Daisy, J. Eliza and K. A. Mohamed Farook, *J. Ethnopharmacol.*, 2009, 126, 339–  
9 344.
- 10 22 S. Singh, R. K. Sharma, S. Malhotra, R. Pothuraju, U. K. Shandilya and A. Kumar,  
11 *Indian Journal of Dairy Science.*, 2012, 65, 305–313.
- 12 23 S. Basannavar, R. Pothuraju and R. K. Sharma. *J. Sci. Food Agric.* 2014, 94, 2712-7.
- 13 24 D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher and R. C.  
14 Turner, *Diabetologia.*, 1985, 28, 412–419.
- 15 25 M. Kumar, S. Rakesh, R. Nagpal, R. Hemalatha, A. Ramakrishna, V. Sudarshan, R.  
16 Ramagoni, M. Shujauddin, V. Verma, A. Kumar, A. Tiwari, B. Singh and R. Kumar,  
17 *Nutrition.*, 2012, 29, 574–579.
- 18 26 K. Lee, K. Paek, H. Y. Lee, J. H. Park and Y. Lee, *J. Appl. Microbiol.*, 2007,103,  
19 1140–1146.
- 20 27 S. A. Everson, D. E. Goldberg, S. P. Helmrich, T. A. Lakka, J. W. Lynch, G. A. Kalpan  
21 and J. T. Salonen, *Diabetes Care.*, 1998, 21, 1637–1643.
- 22 28 C. De Luca and J. M. Olefsky, *FEBS Lett.*, 2008, 582, 97–105.
- 23 29 R. Paoletti, C. Bolego, A. Poli and A. Cignarella, *Vasc. Health Risk Manag.*, 2006, 2,  
24 145–152.
- 25 30 S. E. Shoelson, J. Lee and A. B. Goldfine, *J. Clin. Invest.*, 2006, 116, 1793–1801.

- 1 31 M. Manco, A. Bertuzzi, S. Salinari, A. Scarfone, M. Calvani, A. V. Greco and G.  
2 Mingrone, *Br. J. Nutr.*, 2004a, 92, 895–903.
- 3 32 M. Manco, M. Calvani and G. Mingrone, *Diabetes Obes. Metab.*, 2004b, 6, 402–413.
- 4 33 L. X. Wang, K. Liu and D. W. Gao, *World J. Gastroenterol.*, 2013, 19, 3150–3156.
- 5 34 A. Ralph and G. J. Provan, Phytoprotectants. In Human Nutrition and Dietetics, ed.  
6 J.S.Garrow, W.P.T.James and A.Ralph, 417-26. Edinburgh,Churchill Livingstone.  
7 2000.
- 8 35 N. Takemura, T. Okubo and K. Sonoyama, *Exp. Biol. Med.* 2010, 235, 849–856.
- 9 36 S. Kondo, J. Z. Xiao, T. Satoh, T. Odamaki, S. Takahashi, H. Sugahara, T. Yaeshima,  
10 K. Iwatsuki, A. Kamei and K. Abe, *Biosci. Biotechnol. Biochem.*, 2010, 74, 1656–1661.
- 11 37 A. Yagi, J. Nakamori, T. Yamada, H. Iwase, T. Tanaka, Y. Kaneo, J. Qiu and S.  
12 Orndorff, *J. Nutr.*, 2000, 130, 2471–2477.
- 13 38 D. B. West, F.Y. Blohm, A. A. Truett AA, et al. *J. Nutr.* 2000, 130, 2471–2477.
- 14 39 G. Musso, R. Gambino and M. Cassader, *Annu. Rev. Med.*, 2011, 62, 361–380.
- 15 40 C. L. Ohland and W. K. Macnaughton, *Am. J. Physiol. Gastrointest. Liver Physiol.*,  
16 2010, 298, 807–819.
- 17 41 C. Ulbricht, J. Armstrong, E. Basch, S. Basch, S. Bent, C. Dacey, S. Dalto, I. Foppa, N.  
18 Giese, P. Hammerness, C. Kirkwood, D. Sollars, S. Tanguay-Colucci and W. Weissner,  
19 *J. Herb Pharmacother.*, 2008, 7, 279-323.

## 20 **List of Figure legends**

21 Fig 1 – Effect of different treatments on a) oral glucose tolerance test (OGTT) b) AUC in  
22 mice fed with high fat diet. Values are expressed as mean  $\pm$  SEM. (n=6, <sup>a-b</sup>Mean values with  
23 unlike superscript letters were significantly different (p<0.05 and p<0.01).

24

25 Fig 2 – Effect of different treatments on fasting blood glucose levels in mice fed with high fat  
26 diet. <sup>a-b</sup>Mean values with different superscripts differ significantly (p<0.05).

1

2 Fig 3 – Effect of different treatments on photomicrographs of a) hematoxylin and eosin of  
 3 adipose tissue (200x) (b) Adipocyte mean area ( $\mu\text{m}^2$ ) and cell number in mice fed with high  
 4 fat diet. Values are expressed as mean  $\pm$  SEM (n=3, p<0.001).

5

6 Fig 4 – Effect of different treatments on mRNA expression levels of different genes in mice  
 7 fed with high fat diet. Values are expressed as mean  $\pm$  SEM (n=3). <sup>a-b</sup>Mean values with  
 8 different superscripts differ significantly (p<0.05).

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23 Table 1 Composition of different diets

Components	Control Diet (%)	HFD (%)
Starch	53	25
Casein	20	20
Sucrose	10	10
Soyabean oil	7	7
Lard	0	28
Cellulose	5	5

Vitamin mixture (AOAC, 1990)	1	1
Mineral mixture (AOAC, 1990)	3.5	3.5
Choline chloride	0.2	0.2
Methionine	0.3	0.3

---

Table 2 Sequence of primers used for quantitative real time PCR

Gene	Primer sequence (5'-3')	Annealing Temperature (°C)	Size amplification product (bp)
Adiponectin	F - GGATGCTACTGTTGCAAG	60	152
	R - CATGTACACCGTGATGTG		
Leptin	F - TGACACCAAACCCTCATCA	60	213
	R - TCATTGGCTATCTGCAGCAC		
Resistin	F - TTCCTTGTCCTGAACTGCT	60	186
	R - CAAGACTGCTGTGCCTTCTG		
PPAR $\gamma$	F - CTGGCCTCCCTGATGAATAA	60	205
	R - GGCGGTCTCCACTGAGAATA		
UCP2	F - GCCACTTCACTTCTGCCTTC	60	181
	R - GAAGGCATGAACCCCTTGTA		
IL-6	F - AGTTGCCTTCTTGGGACTGA	60	191
	R - CAGAATTGCCATTGCACAAC		
TNF- $\alpha$	F - GTCGTAGCAAACCACCAAG	60	145
	R - AGAGAACCTGGGAGTAGATAAG		
$\beta$ -Actin	F - TGTTACCAACTGGGACGACA	60	165
	R - GGGGTGTTGAAGGTCTCAA		

Table 3 Body weight, organ weights, insulin, IR index, serum and liver lipids

Parameters	CTRL	HFD	HFD + LR17	HFD + AV + LR17	HFD + GS + LR + 17
Body weight (g)					
Initial	22.27 ± 0.80	22.45 ± 1.10	22.60 ± 0.99	22.52 ± 1.20	22.70 ± 1.32
Final	25.40 ± 0.56 <sup>a</sup>	27.29 ± 0.71 <sup>a</sup>	25.18 ± 0.55 <sup>b</sup>	25.81 ± 0.24 <sup>a</sup>	25.20 ± 0.41 <sup>b</sup>
Epididymal fat (g)	0.56 ± 0.05 <sup>a</sup>	1.10 ± 0.09 <sup>b</sup>	0.55 ± 0.11 <sup>a</sup>	0.68 ± 0.07 <sup>a</sup>	0.64 ± 0.09 <sup>a</sup>
Liver (g)	0.98 ± 0.07	0.96 ± 0.05	0.95 ± 0.02	0.88 ± 0.07	0.83 ± 0.08
Kidney (g)	0.36 ± 0.04	0.40 ± 0.05	0.42 ± 0.02	0.41 ± 0.01	0.33 ± 0.03
Insulin (pmol/l)	80.58 ± 5.74 <sup>a</sup>	172.9 ± 9.28 <sup>b</sup>	76.19 ± 9.54 <sup>a</sup>	98.14 ± 8.07 <sup>a</sup>	86.51 ± 5.89 <sup>a</sup>
HOMA-IR index values	3.03 ± 0.40 <sup>a</sup>	9.35 ± 1.31 <sup>b</sup>	2.53 ± 0.27 <sup>a</sup>	4.16 ± 0.41 <sup>a</sup>	3.45 ± 0.28 <sup>a</sup>
TG (mg/dl)	80.58 ± 5.46 <sup>a</sup>	131.2 ± 6.87 <sup>b</sup>	90.95 ± 7.73 <sup>a</sup>	87.64 ± 6.85 <sup>a</sup>	84.45 ± 8.69 <sup>a</sup>
TC (mg/dl)	97.81 ± 4.54	137.8 ± 5.21	90.95 ± 2.74	96.58 ± 3.86	111.4 ± 5.58
HDL-C (mg/dl)	73.80 ± 2.29	78.42 ± 6.06	74.5 ± 6.21	67.18 ± 9.16	89.35 ± 4.94
LDL-C (mg/dl)	12.27 ± 1.22	16.68 ± 1.82	17.38 ± 1.64	16.96 ± 2.60	18.41 ± 2.70
VLDL-C (mg/dl)	16.12 ± 1.09	21.24 ± 1.85	18.19 ± 1.54	17.06 ± 1.15	16.29 ± 1.37
TG (mg/g liver tissue)	11.94 ± 1.00 <sup>a</sup>	18.45 ± 0.52 <sup>b</sup>	11.93 ± 1.01 <sup>a</sup>	9.90 ± 1.42 <sup>a</sup>	13.46 ± 0.60 <sup>a</sup>
TC (mg/g liver tissue)	1.59 ± 0.19	2.83 ± 0.23	1.45 ± 0.20	2.06 ± 0.21	1.90 ± 0.21

SM=skim milk, HFD=high fat diet and IR=insulin resistance

<sup>a-b</sup>Mean values within a row with unlike superscript letters were significantly different (p<0.05, Tukey's test)







Fig. 1

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17

1

2



3

4 **Fig. 2**

5

6

7

8

9

10

11

12

13

14

15

16

17


18

19


20

21


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24




**CTRL**




**HFD**



**HFD-LR**




**HFD-AVLR**



**HFD-GSLR**

a)



1  
2  
3

4  
5

b)

6

7

Fig. 3

8

9

10

11

12


13

14

15

16

17




8 **Fig. 4**

Food & Function Accepted Manuscript



High fat diet (HFD)




*Lactobacillus rhamnosus*




*Aloe vera*



*Gymnema sylvestre*



C57BL/6J mice



After 12 weeks

- Body weight ↓
- FBG ↓
- Epididymal fat mass ↓
- Serum TG ↓
- Liver TG & TC ↓
- Serum Insulin ↓
- Adipocyte size ↓
- Adiponectin ↑
- Leptin ↓
- UCP2 ↑
- TNF- $\alpha$  ↓